Cristina Arias / Cover / Getty Images
TAKEAWAYS KEY
- Swiss drugmaker Roche plans to invest $50 billion over the next five-years in the U.S., creating more than 12,000.
- Roche is the latest of a number of large companies to boost their presence in the US since President Donald Trump’s election.
- Apple, TSMC, as well as Swiss drugmaker Novartis, have all announced plans to expand their operations in the U.S. over the past few months.
Swiss drugmaker Roche announced plans to invest $50 billion dollars in the U.S. This is the latest of a number of large companies that have increased their presence in this country since Donald Trump took office.
The company stated that it would invest $50 billion in the U.S. for the next five-year period, creating over 12,000 jobs. Roche said that 1,000 of the jobs will be within the company and the remainder “will support new US manufacturing capabilities.” It claimed to employ more than 25,000 employees in 24 locations across eight states of the U.S.
Other companies that have announced plans in recent months to increase their U.S. presence as Trump implements tariffs include Apple (AAPL), which said it would spend $500 billion in the U.S. over the next four years, and chipmaking giant Taiwan Semiconductor Manufacturing Company (TSM), which is planning a $100 billion outlay in U.S.-based manufacturing facilities. The prospect of pharma tariffs are also weighing on Roche and Novartis (NVS), which this month announced plans to invest $23 billion in the U.S.
Roche has been expanding its weight-loss drug business in the U.S., and announced on Tuesday a 900 000 square foot facility to support next-generation drugs in this field. It also announced plans for expanding and upgrading its innovative medicines and diagnoses operations in Kentucky. Indiana, New Jersey. Oregon and California. It expects to build a new gene therapy center in Pennsylvania, a continuous glucose monitoring facility in Indiana, and a new research and development center in Massachusetts.
Thomas Schinecker, CEO, said that the investments announced today demonstrate our commitment to research and development in the US.
